Latest news with #FrankWeber
Yahoo
4 days ago
- Business
- Yahoo
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Vivoryon Therapeutics N.V. Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congress of the European Renal Association in Vienna, Austria, today, June 6, 2025. 'We are delighted that the results of the Phase 2 program were accepted for presentation at the ERA 2025 congress. This allowed Vivoryon to share the outstanding improvements of varoglutamstat on kidney function (eGFR) with the scientific and medical expert community in the kidney space,' said Frank Weber, MD, CEO of Vivoryon. Presentation Highlights Varoglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with potent anti-inflammatory and anti-fibrotic effects. VIVIAD and VIVA-MIND, two independent Phase 2 studies in the EU and U.S. showed a statistically significant and clinically meaningful improvement in a prospectively defined kidney function parameter, eGFR, in an elderly patient population. This improvement was consistent in both trials independently, replicated in the meta-analysis and pooled analysis, and provides converging evidence for this finding. Statistically significant differences between varoglutamstat and placebo were first observed at week 24 and were sustained until week 96. The meta-analysis also confirmed a substantially larger effect size in study participants with diabetes compared to those without diabetes. The next step is planned to be a dedicated Phase 2b trial in patients with diabetic kidney disease (patients with diabetes and chronic kidney disease stage 3b/4). The main goal will be to investigate the efficacy on eGFR in this patient population and to obtain additional information on a potential effect on proteinuria and other kidney specific markers. Presentation Details Date: June 6, 2025 Presentation time: 8:15 am CEST as part of the focused oral session Title: Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studies Venue: Vienna, Austria Presenter: Frank Weber, MD, CEO of Vivoryon Therapeutics ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.
Yahoo
4 days ago
- Health
- Yahoo
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congress of the European Renal Association in Vienna, Austria, today, June 6, 2025. 'We are delighted that the results of the Phase 2 program were accepted for presentation at the ERA 2025 congress. This allowed Vivoryon to share the outstanding improvements of varoglutamstat on kidney function (eGFR) with the scientific and medical expert community in the kidney space,' said Frank Weber, MD, CEO of Vivoryon. Presentation HighlightsVaroglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with potent anti-inflammatory and anti-fibrotic effects. VIVIAD and VIVA-MIND, two independent Phase 2 studies in the EU and U.S. showed a statistically significant and clinically meaningful improvement in a prospectively defined kidney function parameter, eGFR, in an elderly patient population. This improvement was consistent in both trials independently, replicated in the meta-analysis and pooled analysis, and provides converging evidence for this finding. Statistically significant differences between varoglutamstat and placebo were first observed at week 24 and were sustained until week 96. The meta-analysis also confirmed a substantially larger effect size in study participants with diabetes compared to those without diabetes. The next step is planned to be a dedicated Phase 2b trial in patients with diabetic kidney disease (patients with diabetes and chronic kidney disease stage 3b/4). The main goal will be to investigate the efficacy on eGFR in this patient population and to obtain additional information on a potential effect on proteinuria and other kidney specific markers. Presentation Details Date: June 6, 2025Presentation time: 8:15 am CEST as part of the focused oral sessionTitle: Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studiesVenue: Vienna, Austria Presenter: Frank Weber, MD, CEO of Vivoryon Therapeutics ### About Vivoryon Therapeutics is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the 'Company'), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'plan,' 'project,' 'predict,' 'should' and 'will' and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company's results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Investor ContactsVivoryon Therapeutics Manuela Bader, Director IR & CommunicationEmail: IR@ LifeSci AdvisorsSandya von der Weid Tel: +41 78 680 05 38Email: svonderweid@ Media ContactTrophic CommunicationsValeria Fisher or Verena SchossmannTel: +49 175 8041816 / +49 151 219 412 77Email: vivoryon@ Attachment 20250606_ERA_VVYSign in to access your portfolio
7NEWS
09-05-2025
- Automotive
- 7NEWS
2027 BMW X7 SUV spied for the first time, set to go electric
The 2027 BMW X7 large SUV has been spied testing after the carmaker confirmed a second generation – which will include a battery-electric iX7 version – expected in showrooms from 2027. The German brand revealed it's working on a second-generation of the X7 SUV – a rival to the Mercedes-Benz GLS, Audi Q7 and Lexus LX – in its latest financial reports. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The report confirmed costs incurred in the carmaker's financials for the new X7 – the first public mention of a successor to the current model – as well as the iX3 battery-electric SUV and new 2026 X5 SUVs. BMW Australia has yet to confirm the next X7 for local showrooms. According to Autocar the new X7 will use a heavily updated version of the current vehicle's Cluster Architecture (CLAR) underpinnings – meaning similar dimensions – and be offered in both petrol-hybrid and electric powertrains. 'We are in a phase where flexibility is required,' BMW R&D boss Frank Weber told Autocar. 'We have to detach ourselves from how we have perceived platforms up to now.' The current X7 – codenamed G07 – is sold in Australia with a choice of 3.0-litre turbocharged petrol and turbo-diesel in-line six-cylinder engines and a 4.4-litre V8 twin-turbocharged petrol M60i flagship. The carmaker recommitted to internal-combustion engines earlier in 2025, saying it will continue to offer V8 engines for certain models. 'V8s are here to stay. There are markets such as the US and Middle East where you cannot replace V8s with inline-six hybrids,' said Mr Weber. 'We will continue to offer V8s.' The current 'S68' V8 in the X7 was adapted to a plug-in hybrid set-up for the BMW M5 performance sedan and wagon, meeting Euro 6d emissions standards and making it a logical fit for the 2027 X7. Electric versions of the X7, badged 'iX7', could use the 800V tech being developed for the battery-electric iX5 expected in showrooms from 2026. Spy shots of the camouflaged SUV show exhaust pipes and heat shields at the rear indicating the vehicle pictured uses internal combustion and is not the battery-electric model. It also reveals an exterior design departing from other BMW SUVs, showing a front-end closer to that of the 7 Series sedan. BMW has said it will roll out its Neue Klasse design language with the next BMW iX3 due to be unveiled at the 2025 Munich motor show in September. 'We will make sure that the form language that we are developing now – and starting this year at the IAA [Munich show] with the first of the Neue Klasse vehicles – will be rolled out over the entire product portfolio, leaving no car behind,' BMW head of design, Adrain van Hooydonk, told Autocar. 'Of course, it would not be good for us or for our customers if there would be a new type of BMW and a 'classic' type of BMW. We're going to change the look and feel of the BMW brand.' Click an image to view the full gallery.
The Advertiser
09-05-2025
- Automotive
- The Advertiser
2027 BMW X7 SUV spied for the first time, set to go electric
The 2027 BMW X7 large SUV has been spied testing after the carmaker confirmed a second generation – which will include a battery-electric iX7 version – expected in showrooms from 2027. The German brand revealed it's working on a second-generation of the X7 SUV – a rival to the Mercedes-Benz GLS, Audi Q7 and Lexus LX – in its latest financial reports. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The report confirmed costs incurred in the carmaker's financials for the new X7 – the first public mention of a successor to the current model – as well as the iX3 battery-electric SUV and new 2026 X5 SUVs. BMW Australia has yet to confirm the next X7 for local showrooms. According to Autocar the new X7 will use a heavily updated version of the current vehicle's Cluster Architecture (CLAR) underpinnings – meaning similar dimensions – and be offered in both petrol-hybrid and electric powertrains. "We are in a phase where flexibility is required," BMW R&D boss Frank Weber told Autocar. "We have to detach ourselves from how we have perceived platforms up to now." The current X7 – codenamed G07 – is sold in Australia with a choice of 3.0-litre turbocharged petrol and turbo-diesel in-line six-cylinder engines and a 4.4-litre V8 twin-turbocharged petrol M60i flagship. The carmaker recommitted to internal-combustion engines earlier in 2025, saying it will continue to offer V8 engines for certain models. "V8s are here to stay. There are markets such as the US and Middle East where you cannot replace V8s with inline-six hybrids," said Mr Weber. "We will continue to offer V8s." The current 'S68' V8 in the X7 was adapted to a plug-in hybrid set-up for the BMW M5 performance sedan and wagon, meeting Euro 6d emissions standards and making it a logical fit for the 2027 X7. Electric versions of the X7, badged 'iX7', could use the 800V tech being developed for the battery-electric iX5 expected in showrooms from 2026. Spy shots of the camouflaged SUV show exhaust pipes and heat shields at the rear indicating the vehicle pictured uses internal combustion and is not the battery-electric model. It also reveals an exterior design departing from other BMW SUVs, showing a front-end closer to that of the 7 Series sedan. BMW has said it will roll out its Neue Klasse design language with the next BMW iX3 due to be unveiled at the 2025 Munich motor show in September. "We will make sure that the form language that we are developing now – and starting this year at the IAA [Munich show] with the first of the Neue Klasse vehicles – will be rolled out over the entire product portfolio, leaving no car behind," BMW head of design, Adrain van Hooydonk, told Autocar. "Of course, it would not be good for us or for our customers if there would be a new type of BMW and a 'classic' type of BMW. We're going to change the look and feel of the BMW brand." Click an image to view the full gallery. MORE: Everything BMW X7 Content originally sourced from: The 2027 BMW X7 large SUV has been spied testing after the carmaker confirmed a second generation – which will include a battery-electric iX7 version – expected in showrooms from 2027. The German brand revealed it's working on a second-generation of the X7 SUV – a rival to the Mercedes-Benz GLS, Audi Q7 and Lexus LX – in its latest financial reports. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The report confirmed costs incurred in the carmaker's financials for the new X7 – the first public mention of a successor to the current model – as well as the iX3 battery-electric SUV and new 2026 X5 SUVs. BMW Australia has yet to confirm the next X7 for local showrooms. According to Autocar the new X7 will use a heavily updated version of the current vehicle's Cluster Architecture (CLAR) underpinnings – meaning similar dimensions – and be offered in both petrol-hybrid and electric powertrains. "We are in a phase where flexibility is required," BMW R&D boss Frank Weber told Autocar. "We have to detach ourselves from how we have perceived platforms up to now." The current X7 – codenamed G07 – is sold in Australia with a choice of 3.0-litre turbocharged petrol and turbo-diesel in-line six-cylinder engines and a 4.4-litre V8 twin-turbocharged petrol M60i flagship. The carmaker recommitted to internal-combustion engines earlier in 2025, saying it will continue to offer V8 engines for certain models. "V8s are here to stay. There are markets such as the US and Middle East where you cannot replace V8s with inline-six hybrids," said Mr Weber. "We will continue to offer V8s." The current 'S68' V8 in the X7 was adapted to a plug-in hybrid set-up for the BMW M5 performance sedan and wagon, meeting Euro 6d emissions standards and making it a logical fit for the 2027 X7. Electric versions of the X7, badged 'iX7', could use the 800V tech being developed for the battery-electric iX5 expected in showrooms from 2026. Spy shots of the camouflaged SUV show exhaust pipes and heat shields at the rear indicating the vehicle pictured uses internal combustion and is not the battery-electric model. It also reveals an exterior design departing from other BMW SUVs, showing a front-end closer to that of the 7 Series sedan. BMW has said it will roll out its Neue Klasse design language with the next BMW iX3 due to be unveiled at the 2025 Munich motor show in September. "We will make sure that the form language that we are developing now – and starting this year at the IAA [Munich show] with the first of the Neue Klasse vehicles – will be rolled out over the entire product portfolio, leaving no car behind," BMW head of design, Adrain van Hooydonk, told Autocar. "Of course, it would not be good for us or for our customers if there would be a new type of BMW and a 'classic' type of BMW. We're going to change the look and feel of the BMW brand." Click an image to view the full gallery. MORE: Everything BMW X7 Content originally sourced from: The 2027 BMW X7 large SUV has been spied testing after the carmaker confirmed a second generation – which will include a battery-electric iX7 version – expected in showrooms from 2027. The German brand revealed it's working on a second-generation of the X7 SUV – a rival to the Mercedes-Benz GLS, Audi Q7 and Lexus LX – in its latest financial reports. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The report confirmed costs incurred in the carmaker's financials for the new X7 – the first public mention of a successor to the current model – as well as the iX3 battery-electric SUV and new 2026 X5 SUVs. BMW Australia has yet to confirm the next X7 for local showrooms. According to Autocar the new X7 will use a heavily updated version of the current vehicle's Cluster Architecture (CLAR) underpinnings – meaning similar dimensions – and be offered in both petrol-hybrid and electric powertrains. "We are in a phase where flexibility is required," BMW R&D boss Frank Weber told Autocar. "We have to detach ourselves from how we have perceived platforms up to now." The current X7 – codenamed G07 – is sold in Australia with a choice of 3.0-litre turbocharged petrol and turbo-diesel in-line six-cylinder engines and a 4.4-litre V8 twin-turbocharged petrol M60i flagship. The carmaker recommitted to internal-combustion engines earlier in 2025, saying it will continue to offer V8 engines for certain models. "V8s are here to stay. There are markets such as the US and Middle East where you cannot replace V8s with inline-six hybrids," said Mr Weber. "We will continue to offer V8s." The current 'S68' V8 in the X7 was adapted to a plug-in hybrid set-up for the BMW M5 performance sedan and wagon, meeting Euro 6d emissions standards and making it a logical fit for the 2027 X7. Electric versions of the X7, badged 'iX7', could use the 800V tech being developed for the battery-electric iX5 expected in showrooms from 2026. Spy shots of the camouflaged SUV show exhaust pipes and heat shields at the rear indicating the vehicle pictured uses internal combustion and is not the battery-electric model. It also reveals an exterior design departing from other BMW SUVs, showing a front-end closer to that of the 7 Series sedan. BMW has said it will roll out its Neue Klasse design language with the next BMW iX3 due to be unveiled at the 2025 Munich motor show in September. "We will make sure that the form language that we are developing now – and starting this year at the IAA [Munich show] with the first of the Neue Klasse vehicles – will be rolled out over the entire product portfolio, leaving no car behind," BMW head of design, Adrain van Hooydonk, told Autocar. "Of course, it would not be good for us or for our customers if there would be a new type of BMW and a 'classic' type of BMW. We're going to change the look and feel of the BMW brand." Click an image to view the full gallery. MORE: Everything BMW X7 Content originally sourced from: The 2027 BMW X7 large SUV has been spied testing after the carmaker confirmed a second generation – which will include a battery-electric iX7 version – expected in showrooms from 2027. The German brand revealed it's working on a second-generation of the X7 SUV – a rival to the Mercedes-Benz GLS, Audi Q7 and Lexus LX – in its latest financial reports. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The report confirmed costs incurred in the carmaker's financials for the new X7 – the first public mention of a successor to the current model – as well as the iX3 battery-electric SUV and new 2026 X5 SUVs. BMW Australia has yet to confirm the next X7 for local showrooms. According to Autocar the new X7 will use a heavily updated version of the current vehicle's Cluster Architecture (CLAR) underpinnings – meaning similar dimensions – and be offered in both petrol-hybrid and electric powertrains. "We are in a phase where flexibility is required," BMW R&D boss Frank Weber told Autocar. "We have to detach ourselves from how we have perceived platforms up to now." The current X7 – codenamed G07 – is sold in Australia with a choice of 3.0-litre turbocharged petrol and turbo-diesel in-line six-cylinder engines and a 4.4-litre V8 twin-turbocharged petrol M60i flagship. The carmaker recommitted to internal-combustion engines earlier in 2025, saying it will continue to offer V8 engines for certain models. "V8s are here to stay. There are markets such as the US and Middle East where you cannot replace V8s with inline-six hybrids," said Mr Weber. "We will continue to offer V8s." The current 'S68' V8 in the X7 was adapted to a plug-in hybrid set-up for the BMW M5 performance sedan and wagon, meeting Euro 6d emissions standards and making it a logical fit for the 2027 X7. Electric versions of the X7, badged 'iX7', could use the 800V tech being developed for the battery-electric iX5 expected in showrooms from 2026. Spy shots of the camouflaged SUV show exhaust pipes and heat shields at the rear indicating the vehicle pictured uses internal combustion and is not the battery-electric model. It also reveals an exterior design departing from other BMW SUVs, showing a front-end closer to that of the 7 Series sedan. BMW has said it will roll out its Neue Klasse design language with the next BMW iX3 due to be unveiled at the 2025 Munich motor show in September. "We will make sure that the form language that we are developing now – and starting this year at the IAA [Munich show] with the first of the Neue Klasse vehicles – will be rolled out over the entire product portfolio, leaving no car behind," BMW head of design, Adrain van Hooydonk, told Autocar. "Of course, it would not be good for us or for our customers if there would be a new type of BMW and a 'classic' type of BMW. We're going to change the look and feel of the BMW brand." Click an image to view the full gallery. MORE: Everything BMW X7 Content originally sourced from:
Perth Now
09-05-2025
- Automotive
- Perth Now
2027 BMW X7 SUV spied for the first time, set to go electric
The 2027 BMW X7 large SUV has been spied testing after the carmaker confirmed a second generation – which will include a battery-electric iX7 version – expected in showrooms from 2027. The German brand revealed it's working on a second-generation of the X7 SUV – a rival to the Mercedes-Benz GLS, Audi Q7 and Lexus LX – in its latest financial reports. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. Supplied Credit: CarExpert The report confirmed costs incurred in the carmaker's financials for the new X7 – the first public mention of a successor to the current model – as well as the iX3 battery-electric SUV and new 2026 X5 SUVs. BMW Australia has yet to confirm the next X7 for local showrooms. According to Autocar the new X7 will use a heavily updated version of the current vehicle's Cluster Architecture (CLAR) underpinnings – meaning similar dimensions – and be offered in both petrol-hybrid and electric powertrains. 'We are in a phase where flexibility is required,' BMW R&D boss Frank Weber told Autocar. 'We have to detach ourselves from how we have perceived platforms up to now.' Supplied Credit: CarExpert The current X7 – codenamed G07 – is sold in Australia with a choice of 3.0-litre turbocharged petrol and turbo-diesel in-line six-cylinder engines and a 4.4-litre V8 twin-turbocharged petrol M60i flagship. The carmaker recommitted to internal-combustion engines earlier in 2025, saying it will continue to offer V8 engines for certain models. 'V8s are here to stay. There are markets such as the US and Middle East where you cannot replace V8s with inline-six hybrids,' said Mr Weber. 'We will continue to offer V8s.' The current 'S68' V8 in the X7 was adapted to a plug-in hybrid set-up for the BMW M5 performance sedan and wagon, meeting Euro 6d emissions standards and making it a logical fit for the 2027 X7. Supplied Credit: CarExpert Electric versions of the X7, badged 'iX7', could use the 800V tech being developed for the battery-electric iX5 expected in showrooms from 2026. Spy shots of the camouflaged SUV show exhaust pipes and heat shields at the rear indicating the vehicle pictured uses internal combustion and is not the battery-electric model. It also reveals an exterior design departing from other BMW SUVs, showing a front-end closer to that of the 7 Series sedan. Supplied Credit: CarExpert Current X7 Credit: CarExpert BMW has said it will roll out its Neue Klasse design language with the next BMW iX3 due to be unveiled at the 2025 Munich motor show in September. 'We will make sure that the form language that we are developing now – and starting this year at the IAA [Munich show] with the first of the Neue Klasse vehicles – will be rolled out over the entire product portfolio, leaving no car behind,' BMW head of design, Adrain van Hooydonk, told Autocar. 'Of course, it would not be good for us or for our customers if there would be a new type of BMW and a 'classic' type of BMW. We're going to change the look and feel of the BMW brand.' Click an image to view the full gallery. MORE: Everything BMW X7
